Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
Lykos Therapeutics has announced a reorganization to best support the company as it works to address the resubmission of its new drug application (NDA) for midomafetamine capsules for the treatment of post-traumatic stress disorder (PTSD) in adults. 16 August 2024
German infectious disease specialist AiCuris Anti-infective Cures has announced the appointment of Cynthia Wat as chief medical officer (CMO). 30 July 2024
Ophirex, a registered public benefit corporation developing an oral field treatment to address the global unmet medical needs of snakebite victims, has announced the appointment of Jeremy Gowler as chief executive. 15 July 2024
US drugmaker AbbVie has announced that Roopal Thakkar, who currently serves as senior vice president, chief medical officer, global therapeutics, has been appointed to the position of executive vice president, research and development, and chief scientific officer (CSO). 10 July 2024
Swiss biopharma company Relief Therapeutics today announced that its collaboration partner, Acer Therapeutics for ACER-001 (sodium phenylbutyrate) for oral suspension for the treatment of patients with urea cycle disorders (UCDs), has resubmitted its New Drug Application (NDA) for ACER-001 to the US Food and Drug Administration (FDA). 18 July 2022
Swiss contract development and manufacturing organization Lonza has announced that its board of directors has appointed Maria Soler Nunez as its new head of group operations. 4 July 2022
Israeli generics giant Teva Pharmaceutical Industries announced today the appointment of Eric Hughes as executive vice president, global R&D and chief medical officer. 1 July 2022
US pharma giant Merck & Co has announced that Chirfi Guindo will lead Human Health Marketing as chief marketing officer for Merck Human Health, and will join Merck’s executive team, effective July 1, 2022. 23 June 2022
Privately-held contract research organization BioAgilytix Labs has announced the appointment of Euan Menzies as chairman and chief executive. 21 June 2022
An Expert View from Robert Wessman, chairman and CEO at global pharmaceutical company Alvogen, and founder and chairman at biopharma specialist, Alvotech. 25 May 2022
Privately-held Swiss drugmaker Helsinn Group has announced the appointment of Dr Melanie Rolli as group chief operating officer (COO), effective June 1, 2022. 19 May 2022
German firm Fresenius Kabi, a specialist in medicines and technologies for infusion, transfusion and clinical nutrition, has recruited Brandee Pappalardo as senior vice president and chief medical officer for North America. 19 May 2022
Cerevance, a private, UK headquartered clinical-stage drug discovery and development company focused on central nervous system diseases, today announced the appointment of Craig Thompson as chief executive (CEO). 20 April 2022
Danish CNS specialist Lundbeck said on Friday it has has appointed Joerg Hornstein as chief financial officer (CFO) and member of its executive management. He will assume the role no later than September 1, 2022, and he will be registered with the Danish Business Authority. 11 April 2022
UK endocrine diseases specialist Diurnal Group today announced that, following 14 years with the company, Martin Whitaker has decided to step down as chief executive (CEO) and a member of the board of Diurnal, with immediate effect, to enable him to pursue other business opportunities. 4 April 2022
US pharma giant Merck & Co today announced today that Dr Roy Baynes, head of global clinical development (GCD) and chief medical officer, Merck Research Laboratories (MRL), will be retiring from Merck in July. 23 March 2022
The end of an era is approaching at Anglo-Swedish drugmaker AstraZeneca as Leif Johansson, non-executive chairman of the board, confirmed that he will be retiring in 2023. 23 February 2022
US cancer therapies specialist Karyopharm Therapeutics saw its shares drop as much as 31% Tuesday, on the news that its chief medical officer was stepping down, even though it also announced two prominent research appointments. 23 February 2022
Danish dermatology specialist LEO Pharma has appointed Brian Hilberdink new executive vice president and president of LEO Pharma Inc in the USA, effective March 14, 2022. 21 February 2022
Japan’s largest drugmaker Takeda Pharmaceuticals today announced changes to its Growth and Emerging Markets Business Unit (GEM BU) leadership team as part of the company’s broader corporate leadership team changes to accelerate business growth and the delivery of transformational medicines to patients. 7 February 2022